Parkinson Disease (PD)NCT07494461
Inhibitory Control and Gait Adaptability in Parkinson's Disease
An observational study of Parkinson Disease (PD), run by National Yang Ming Chiao Tung University at 2 sites in Taiwan.
Trial summary
People with Parkinson's disease (PD) may have difficulty stopping or changing their movements, especially when walking around obstacles. The goal of this observational study is to learn if a specific cognitive function, called inhibitory control (the ability to stop or control actions) is associated with gait… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Parkinson Disease (PD)
- How many people
- 50 participants
- Where
- 2 sitesTaiwan
- Study dates
- 1 Apr 2026to 31 Aug 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Community
Who may be able to join
- A clinical diagnosis of idiopathic Parkinson's disease;
- Stable use of prescribed antiparkinsonian medication for at least two weeks;
- Modified Hoehn and Yahr stage I to III;
- Age between 18 and 80 years;
- Ability to ambulate independently for at least 30 meters without assistive devices;
- A Mini-Mental State Examination (MMSE) score of ≥ 24;
- Corrected vision and hearing sufficient to effectively receive external stimuli
Who cannot join
- The presence of any neurological, musculoskeletal, or cardiovascular disorders that could affect participation in this study;
- The presence of psychiatric disorders that could interfere with the ability to follow instructions or comply with study procedures;
- A history of brain surgery, such as deep brain stimulation (DBS)
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan2 sites
National Yang Ming Chiao Tung University
Taipei
Yea-Ru Yang, Professor, 886-2-2826-7279, yryang@nycu.edu.tw
National Yang Ming Chiao Tung University
Taipei
About this study
Official title: Relationship Between Inhibitory Control and Gait Adaptability During Obstacle Crossing in People With Parkinson's Disease
People with Parkinson's disease (PD) may have difficulty stopping or changing their movements, especially when walking around obstacles.
The goal of this observational study is to learn if a specific cognitive function, called inhibitory control (the ability to stop or control actions) is associated with gait adaptability in people with Parkinson's disease. Gait adaptability means the ability to adjust how a person walks in response to changes in the environment, such as stepping over obstacles.
Read more
The main questions the study aims to answer are:
- If brain activation related to inhibitory control, measured by EEG, is associated with gait adaptability during obstacle crossing in people with Parkinson's disease?
- If behavioral inhibitory control is associated with gait adaptability during obstacle crossing in people with Parkinson's disease?
Participants take part in one study visit. During this visit, participants complete simple thinking tests, have their brain activity recorded using EEG, and perform walking tasks that include stepping over obstacles.
- Conditions
- Parkinson Disease (PD)
- Keywords
- Electroencephalography, Executive function, Obstacle crossing
- Medical subject headings
- Parkinson Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
Event-related potential - N2
Measure event-related potential through electroencephalography during the Go/No-go test
Measured: 1 day
Event-related potential - P300
Measure event-related potential through electroencephalography during the Go/No-go test
Measured: 1 day
Stroop color and word test
Record numbers of corrected color words which the subject responds within 45 sec
Measured: 1 day
Step width
Using the GAITRite system to measure step width
Measured: 1 day
Stride length/Step length
Using the GAITRite system to measure stride length and step length during obstacle crossing
Measured: 1 day
Single support time
Using the GAITRite system to measure single support time during obstacle crossing
Measured: 1 day
Gait speed
Gait speed during obstacle crossing was measured using the GAITRite system. Continuous obstacle-crossing walking performance was assessed using the GaitUp system.
Measured: 1 day
Stride length
Using the GaitUp system to measure stride length during continuous obstacle-crossing walking.
Measured: 1 day
Swing phase
Using the GaitUp system to measure swing phase during continuous obstacle-crossing walking.
Measured: 1 day
Swing width
Using the GaitUp system to measure swing width during continuous obstacle-crossing walking.
Measured: 1 day
Four Square Step Test
The Four Square Step Test is a test used to assess the ability to step over objects and measures the time in seconds to navigate all four squares.
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2026
- Study start1 Apr 2026 (estimated)
- Primary completion31 Aug 2029 (estimated)
- Study completion31 Aug 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson Disease (PD)Studies of the same condition, open and under way.
- More trials run by National Yang Ming Chiao Tung UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Yang Ming Chiao Tung University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yea-Ru Yang, National Yang Ming Chiao Tung University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07494461
- Sponsor's protocol ID
- NYCU114252AF1
- Status last verified
- Mar 2026
- First submitted
- 20 Mar 2026
- Last updated
- 27 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Relationship Between Inhibitory Control and Gait Adaptability During Obstacle Crossing in People With Parkinson's Disease
- ClinicalTrials.gov ID
- NCT07494461
- Acronym / sponsor ID
- NYCU114252AF1
- Conditions
- Parkinson Disease (PD)
- Keywords
- Electroencephalography, Executive function, Obstacle crossing
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- National Yang Ming Chiao Tung UniversityUniversity, hospital or other
- Study start
- 1 Apr 2026 (estimated)
- Primary completion
- 31 Aug 2029 (estimated)
- Study completion
- 31 Aug 2029 (estimated)
- First posted
- 27 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
People with Parkinson's disease (PD) may have difficulty stopping or changing their movements, especially when walking around obstacles.
The goal of this observational study is to learn if a specific cognitive function, called inhibitory control (the ability to stop or control actions) is associated with gait adaptability in people with Parkinson's disease. Gait adaptability means the ability to adjust how a person walks in response to changes in the environment, such as stepping over obstacles.
The main questions the study aims to answer are:
- If brain activation related to inhibitory control, measured by EEG, is associated with gait adaptability during obstacle crossing in people with Parkinson's disease?
- If behavioral inhibitory control is associated with gait adaptability during obstacle crossing in people with Parkinson's disease?
Participants take part in one study visit. During this visit, participants complete simple thinking tests, have their brain activity recorded using EEG, and perform walking tasks that include stepping over obstacles.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Community
Key inclusion criteria (7 listed)
- A clinical diagnosis of idiopathic Parkinson's disease;
- Stable use of prescribed antiparkinsonian medication for at least two weeks;
- Modified Hoehn and Yahr stage I to III;
- Age between 18 and 80 years;
- Ability to ambulate independently for at least 30 meters without assistive devices;
Key exclusion criteria (3 listed)
- The presence of any neurological, musculoskeletal, or cardiovascular disorders that could affect participation in this study;
- The presence of psychiatric disorders that could interfere with the ability to follow instructions or comply with study procedures;
- A history of brain surgery, such as deep brain stimulation (DBS)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Event-related potential - N2
Time frame: 1 day
Measure event-related potential through electroencephalography during the Go/No-go test
Event-related potential - P300
Time frame: 1 day
Measure event-related potential through electroencephalography during the Go/No-go test
Stroop color and word test
Time frame: 1 day
Record numbers of corrected color words which the subject responds within 45 sec
Step width
Time frame: 1 day
Using the GAITRite system to measure step width
Stride length/Step length
Time frame: 1 day
Using the GAITRite system to measure stride length and step length during obstacle crossing
Single support time
Time frame: 1 day
Using the GAITRite system to measure single support time during obstacle crossing
Gait speed
Time frame: 1 day
Gait speed during obstacle crossing was measured using the GAITRite system. Continuous obstacle-crossing walking performance was assessed using the GaitUp system.
Stride length
Time frame: 1 day
Using the GaitUp system to measure stride length during continuous obstacle-crossing walking.
Swing phase
Time frame: 1 day
Using the GaitUp system to measure swing phase during continuous obstacle-crossing walking.
Swing width
Time frame: 1 day
Using the GaitUp system to measure swing width during continuous obstacle-crossing walking.
Four Square Step Test
Time frame: 1 day
The Four Square Step Test is a test used to assess the ability to step over objects and measures the time in seconds to navigate all four squares.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2026.
Related trials for Parkinson Disease (PD)
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
Active, not recruitingPhase 2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Carcinoma, Non-Small-Cell Lung
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease (PD), run by National Yang Ming Chiao Tung University at 2 sites in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yea-Ru Yang, PhD (+886228267279, yryang@nycu.edu.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Event-related potential - N2 (time frame: 1 day). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.